CPAP therapy in patients with obstructive sleep apnea undergoing pulmonary vein isolation resulted in a higher 12-month AF-free survival rate compared to CPAP nonusers (71.9% vs. 36.7%; p=0.01).
Cohort (n=62)
Does continuous positive airway pressure (CPAP) therapy reduce atrial fibrillation recurrence in patients with obstructive sleep apnea undergoing pulmonary vein isolation?
CPAP therapy significantly improves arrhythmia-free survival in patients with obstructive sleep apnea undergoing pulmonary vein isolation for atrial fibrillation.
Tasa de eventos absoluta: 71.9% vs 36.7%
valor p: p=0.01
OBJECTIVES: The aim of this study was to examine the effect of continuous positive airway pressure (CPAP) therapy on atrial fibrillation (AF) recurrence in patients with obstructive sleep apnea (OSA) undergoing pulmonary vein isolation (PVI). BACKGROUND: OSA is a predictor of AF recurrence following PVI. However, the impact of CPAP therapy on PVI outcome in patients with OSA is poorly known. METHODS: Among 426 patients who underwent PVI between 2007 and 2010, 62 patients had a polysomnography-confirmed diagnosis of OSA. While 32 patients were "CPAP users" the remaining 30 patients were "CPAP nonusers." The recurrence of any atrial tachyarrhythmia, use of antiarrhythmic drugs, and need for repeat ablations were compared between the groups during a follow-up period of 12 months. Additionally, the outcome of patients with OSA was compared to a group of patients from the same PVI cohort without OSA. RESULTS: CPAP therapy resulted in higher AF-free survival rate (71.9% vs. 36.7%; p = 0.01) and AF-free survival off antiarrhythmic drugs or repeat ablation following PVI (65.6% vs. 33.3%; p = 0.02). AF recurrence rate of CPAP-treated patients was similar to a group of patients without OSA (HR: 0.7, p = 0.46). AF recurrence following PVI in CPAP nonuser patients was significantly higher (HR: 2.4, p < 0.02) and similar to that of OSA patients managed medically without ablation (HR: 2.1, p = 0.68). CONCLUSIONS: CPAP is an important therapy in OSA patients undergoing PVI that improves arrhythmia free survival. PVI offers limited value to OSA patients not treated with CPAP.
“Our study confirms the expanding body of evidence that treatment of modifiable risk factors has a significant impact on the long-term suppression of atrial fibrillation regardless of the type of therapy offered. Active screening for obstructive sleep apnea in all patients who undergo treatment for atrial fibrillation is imperative as the use of CPAP will influence the outcome of therapy and likely reduce some of the cardiovascular morbidity associated with atrial fibrillation.”
Fein et al. (Tue,) conducted a cohort in Obstructive sleep apnea and atrial fibrillation (n=62). Continuous positive airway pressure (CPAP) therapy vs. CPAP nonusers was evaluated on Atrial fibrillation-free survival rate (p=0.01). CPAP therapy in patients with obstructive sleep apnea undergoing pulmonary vein isolation resulted in a higher 12-month AF-free survival rate compared to CPAP nonusers (71.9% vs. 36.7%; p=0.01).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: